NLX P101

Drug Profile

NLX P101

Alternative Names: GAD gene therapy; Glutamic acid decarboxylase gene therapy; STN AAV-GAD gene therapy

Latest Information Update: 06 Jun 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cornell University; Neurologix
  • Developer Neurologix
  • Class Antiparkinsonians; Gene therapies
  • Mechanism of Action GABA modulators; Glutamate modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 22 Apr 2013 Diamyd Medical is now called Mertiva
  • 16 Mar 2012 Discontinued - Phase-II for Parkinson's disease in USA (Intracerebral)
  • 20 Feb 2012 Neurologix terminates long term trial in Parkinson's disease in USA (NCT01301573)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top